PHP Biotech has identified the urokinase plasminogen activator receptor (uPAR) as the cell surface protein that binds and internalizes PHP53-nb, the company’s investigational p53 restoring nanobody. The finding explains how PHP53-nb enters tumor cells, supports its documented tumor selectivity, and connects the program to a receptor that is already imaged in patients and is now the target of CAR T programs at leading research institutions.

This article explains what uPAR is, why the identification matters, how the internalization cascade works, and what it could mean for the future of the PHP53-nb platform.

uPAR is a protein found on the surface of cells that helps tumors break down surrounding tissue, invade, and spread. For roughly three decades it has been one of the most consistent markers of aggressive cancer: the more uPAR a tumor expresses, the more likely it is to invade, metastasize, and recur.

uPAR is found in a broad set of 30+ cancer types, including breast, pancreatic, colorectal, and brain tumors, and not only on the cancer cells themselves, but on the supporting stroma that surrounds them.

PHP Biotech identified uPAR as the entry point for PHP53-nb into the tumor cell, the surface receptor that mediates the nanobody’s binding and its internalization into the cytoplasm. Until now, PHP53-nb was known to bind a tumor associated membrane ligand and enter by endocytosis; the receptor itself was not named. Identifying uPAR closes that gap and links PHP53-nb to a large body of existing research on the receptor.

uPAR mediated entry offers a molecular explanation for the tumor selectivity PHP53-nb has shown in prior research. Because uPAR is enriched on aggressive tumor cells and their stroma and comparatively sparse on healthy tissue, a therapeutic that depends on uPAR for entry is expected to concentrate its activity where the receptor is abundant. This is consistent with the low toxicity to normal cells observed in PHP53-nb’s preclinical models.

Potentially, yes. Because clinical grade uPAR-PET imaging agents already exist and are currently used in clinical trials, there is a prospect of identifying patients whose tumors express uPAR before treatment. This companion imaging approach, image the target first, then treat, is something most early stage programs cannot borrow from day one. PHP Biotech has not yet initiated clinical studies, and any patient selection strategy would be defined during clinical development.

Most targeted therapies rely on a single antigen for both recognition and effect; PHP53-nb separates the two, which the company describes as a sharper logic than the single antigen approach prevailing in the field. This could support better patient selection for future clinical trials.

It matters because nanobodies are highly modular. PHP53-nb is a humanized camelid nanobody, small, stable, easily conjugated, and readily engineered into multispecific formats. A binder with a confirmed uPAR mediated internalization route is therefore not just a therapeutic; it is, in principle, a delivery vehicle as well.

The same molecule that carries a p53 pathway restoring mechanism today could be developed into a radioligand, an antibody drug conjugate (ADC), or a bispecific T-cell engager in the future, combining biological tumor suppressor restoration with a cytotoxic payload or with another nanobody that activates T-cells against the most aggressive tumors.

PHP53-nb remains in preclinical development and is investigational; it has not been approved by the FDA or any regulatory authority. The uPAR identification informs the company’s translational strategy, including how tumor selectivity is characterized, how patient populations might be defined, and how the nanobody platform could be extended into additional formats. PHP Biotech will share further updates as the program advances.